Платегра

Платегра (ticagrelor) is an oral antiplatelet medication used to reduce blood clot risk. It belongs to the P2Y12 inhibitor class and is prescribed for cardiovascular conditions. This EU-manufactured drug supports heart health by preventing platelet aggregation. Short-term use may be indicated post-stent or for acute coronary syndromes.

Ticagrelor is primarily used to prevent blood clots in people with cardiovascular conditions such as acute coronary syndromes or after stent placement. It works by inhibiting platelet aggregation, which helps reduce the risk of heart attack or stroke. Patients often ask, 'what is ticagrelor used for' when prescribed for secondary prevention after cardiac events. The medication is also considered for long-term management in certain high-risk patients.

Ticagrelor may cause mild to moderate effects such as shortness of breath, dizziness, or bruising more easily than usual. Some users report fatigue or mild headaches during the initial weeks of treatment. These effects are generally temporary and tend to subside as the body adjusts. Regular monitoring by a healthcare provider is recommended to assess tolerance and efficacy.

Ticagrelor should be taken exactly as prescribed, typically with or without food. It is important to avoid sudden discontinuation unless directed by a doctor, as this may increase clot risk. Patients should inform their healthcare provider about any bleeding disorders, liver issues, or upcoming surgeries. Regular blood tests may be required to monitor platelet function and overall safety.

Ticagrelor can interact with other medications that affect blood clotting or liver enzymes, including certain antidepressants, antifungals, and blood thinners. Grapefruit juice may also interfere with its metabolism. Alcohol use should be limited, as it can increase bleeding risk. Always consult a healthcare provider before combining ticagrelor with other drugs or supplements.